

# Satohiro Masuda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4114381/satohiro-masuda-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

183  
papers

8,160  
citations

48  
h-index

86  
g-index

191  
ext. papers

9,128  
ext. citations

4  
avg, IF

5.59  
L-index

#	Paper	IF	Citations
183	Effect of Itraconazole and Its Metabolite Hydroxyitraconazole on the Blood Concentrations of Cyclosporine and Tacrolimus in Lung Transplant Recipients.. <i>Biological and Pharmaceutical Bulletin</i> , <b>2022</b> , 45, 397-402	2.3	
182	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 150-200	3.2	17
181	Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. <i>Toxicology Letters</i> , <b>2021</b> , 341, 43-50	4.4	1
180	Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 158, 105666	5.1	2
179	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , <b>2021</b> , 11, 1324	4.9	8
178	Influence of Polymorphisms on -Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
177	Increasing Diluent Volume Decreases Bendamustine-Induced Venous Irritation without Reducing the Therapeutic Efficacy. <i>Biological and Pharmaceutical Bulletin</i> , <b>2020</b> , 43, 488-492	2.3	1
176	Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer. <i>Biological and Pharmaceutical Bulletin</i> , <b>2020</b> , 43, 663-668	2.3	2
175	Donor Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
174	Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients. <i>Biological and Pharmaceutical Bulletin</i> , <b>2020</b> , 43, 1600-1603	2.3	3
173	IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA. <i>Neuro-Oncology</i> , <b>2020</b> , 22, iii361-iii361	1	78
172	Comparison of 4 Commercial Immunoassays Used in Measuring the Concentration of Tacrolimus in Blood and Their Cross-Reactivity to Its Metabolites. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 400-406	3.2	0
171	Significance of Ethnic Factors in Immunosuppressive Therapy Management After Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 369-380	3.2	3
170	Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 803-813	3.5	8
169	Statin Intolerance Clinical Guide 2018. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2020</b> , 27, 375-396	4	7
168	Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmethylsalicylic Acid in Japanese Patients with Ulcerative Colitis. <i>Biological and Pharmaceutical Bulletin</i> , <b>2019</b> , 42, 81-86	2.3	5
167	Impact of , and Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	14

166	Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. <i>Acta Pharmacologica Sinica</i> , <b>2019</b> , 40, 151-159	8	13
165	Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	2
164	Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	14
163	Urinary Human Epididymis Secretory Protein 4 as a Useful Biomarker for Subclinical Acute Rejection Three Months after Kidney Transplantation. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	3
162	Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. <i>Biochemical Pharmacology</i> , <b>2019</b> , 170, 113664	6	25
161	The 2nd Symposium Current Status of Reverse Translational Research Conducted by Hospital Pharmacists-Challenges for Screening of Therapeutic Molecular Target and Personalized Medicine-. <i>Yakugaku Zasshi</i> , <b>2019</b> , 139, 899-900	0	
160	Elucidation of Occurrence Mechanism of Dispensing Errors Based on Gaze Movement of Pharmacists Using Eye Tracking Method. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2019</b> , 45, 493-503	0.1	0
159	Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies. <i>Lung Cancer</i> , <b>2019</b> , 130, 5-9	5.9	24
158	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
157	Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2019</b> , 158, 289-296	1.5	21
156	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). <i>Oncology</i> , <b>2018</b> , 94, 289-296	3.6	3
155	Analysis of Questions on Out-of-hospital Prescriptions Related to Laboratory Data. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2018</b> , 44, 229-235	0.1	2
154	Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia in rats. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO3-2-31 <sup>0</sup>		
153	Novel high-sensitive drug detecting, PID method reveals intra-tumor pharmacokinetics of trastuzumab and factors affect to its remarkable heterogeneity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO1-11-18	0	
152	Role of mTOR inhibitors in solid organ transplantation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, SY52-2	0	
151	Relationship between autophagy and acute rejection after kidney transplant. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO1-3-14	0	
150	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10094-10094	2.2	
149	Specification of Start Timing of Medication Support in Patients with Rheumatoid Arthritis. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2018</b> , 44, 261-269	0.1	

148	Analysis of Adverse Drug Reactions on Osimertinib in T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2018</b> , 44, 355-362	0.1	2
147	Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 675-681	3.2	6
146	Drug delivery system in treatment against inflammatory bowel disease: present and future. <i>Drug Delivery System</i> , <b>2018</b> , 33, 397-405	0	1
145	Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats. <i>Journal of Pharmacological Sciences</i> , <b>2018</b> , 138, 214-217	3.7	5
144	Vancomycin induces reactive oxygen species-dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells. <i>European Journal of Pharmacology</i> , <b>2017</b> , 800, 48-56	5.3	34
143	Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis. <i>Pediatric Infectious Disease Journal</i> , <b>2017</b> , 36, 398-400	3.4	8
142	Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , <b>2017</b> , 105, 361-368	2.3	10
141	Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. <i>Scientific Reports</i> , <b>2017</b> , 7, 9661	4.9	23
140	Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 190, 54-67	6.2	7
139	Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 179-85	2.4	2
138	Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. <i>Biological and Pharmaceutical Bulletin</i> , <b>2016</b> , 39, 1331-7	2.3	10
137	Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. <i>Scientific Reports</i> , <b>2016</b> , 6, 27557	4.9	16
136	Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. <i>International Journal of Clinical Oncology</i> , <b>2016</b> , 21, 491-7	4.2	50
135	Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 703-10 <sup>2.8</sup>		9
134	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10127-10127	2.2	2
133	Development and Utility Evaluation of a Compatibility Chart of Injections Commonly Used in the Intensive Care Unit. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2016</b> , 42, 286-294	0.1	3
132	Role of mTOR Inhibitors in Kidney Disease. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	29
131	Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	6

130	Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 663-669	3.2	7
129	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
128	Involvement of intracellular cAMP in epirubicin-induced vascular endothelial cell injury. <i>Journal of Pharmacological Sciences</i> , <b>2016</b> , 130, 33-7	3.7	6
127	Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. <i>Annals of Thoracic Surgery</i> , <b>2016</b> , 102, 1717-1724	2.7	9
126	Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 1191-7	3.5	6
125	Relationship between incident types and impact on patients in drug name errors: a correlational study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , <b>2015</b> , 1, 11	1.8	2
124	Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 989-96	3.5	55
123	Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Biological and Pharmaceutical Bulletin</i> , <b>2015</b> , 38, 1192-8	2.3	13
122	Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. <i>Biological and Pharmaceutical Bulletin</i> , <b>2015</b> , 38, 1410-4	2.3	31
121	Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , <b>2015</b> , 1, 19	1.8	3
120	Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. <i>Biomedical Chromatography</i> , <b>2015</b> , 29, 1309-16	1.7	22
119	Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 51-8	2.8	38
118	Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136994	3.7	71
117	Evaluation of Patient Education System to Improve Their Understanding in Patients Treated with Erlotinib or Gefitinib. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2015</b> , 41, 566-577	0.1	
116	Vancomycin induced renal tubular cell injury by reactive oxygen species generation and mitochondrial dysfunction. <i>FASEB Journal</i> , <b>2015</b> , 29, 777.1	0.9	1
115	Evaluation of teicoplanin concentrations and safety analysis in neonates. <i>International Journal of Antimicrobial Agents</i> , <b>2014</b> , 44, 458-62	14.3	7
114	Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. <i>Transplantation Proceedings</i> , <b>2014</b> , 46, 758-60	1.1	17
113	Conformational change in transfer RNA is an early indicator of acute cellular damage. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 2316-26	12.7	70

112	Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2014</b> , 29, 83-9	2.2	16
111	Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients. <i>Biological and Pharmaceutical Bulletin</i> , <b>2014</b> , 37, 417-23	2.3	5
110	Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e110527	3.7	30
109	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. <i>Annals of Pharmacotherapy</i> , <b>2014</b> , 48, 1159-1165	2.9	20
108	Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2014</b> , 29, 266-71	2.2	6
107	Inhibitory effect of ciprofloxacin on $\beta$ -glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. <i>Biopharmaceutics and Drug Disposition</i> , <b>2014</b> , 35, 275-83	1.7	17
106	Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 910-2	3.8	16
105	Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 356-66	1.9	19
104	Prophylactic effect of calcium channel blockers against oxaliplatin-induced acute peripheral neuropathy (1143.8). <i>FASEB Journal</i> , <b>2014</b> , 28, 1143.8	0.9	
103	Association between decreased expression of GLT-1 derived spinal glutamate accumulation and oxaliplatin-induced mechanical allodynia (1143.1). <i>FASEB Journal</i> , <b>2014</b> , 28, 1143.1	0.9	
102	Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation: analysis of 155 donor-recipient pairs. <i>Hepatology International</i> , <b>2013</b> , 7, 916-22	8.8	3
101	Involvement of riboflavin transporter RFVT2/Slc52a2 in hepatic homeostasis of riboflavin in mice. <i>European Journal of Pharmacology</i> , <b>2013</b> , 714, 281-7	5.3	12
100	Impact of glutathione S-transferase T1 gene polymorphisms on acute cellular rejection in living donor liver transplantation. <i>Transplant Immunology</i> , <b>2013</b> , 28, 14-7	1.7	7
99	Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2013</b> , 432, 689-94	3.4	36
98	Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. <i>Biochemical Pharmacology</i> , <b>2013</b> , 85, 570-82	6	27
97	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. <i>Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 102, 3302-8	3.9	44
96	Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. <i>Biological and Pharmaceutical Bulletin</i> , <b>2013</b> , 36, 1814-21	2.3	26
95	Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. <i>Biological and Pharmaceutical Bulletin</i> , <b>2013</b> , 36, 1221-5	2.3	6



94	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 259-66	2.8	15
93	Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. <i>Liver Transplantation</i> , <b>2012</b> , 18, 1333-42	4.5	132
92	The challenge of acute rejection in intestinal transplantation. <i>Pediatric Surgery International</i> , <b>2012</b> , 28, 855-9	2.1	1
91	Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. <i>British Journal of Pharmacology</i> , <b>2012</b> , 166, 1183-91	8.6	65
90	Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. <i>European Journal of Pharmacology</i> , <b>2012</b> , 696, 143-54	5.3	54
89	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 399-405	3.5	212
88	Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. <i>Biomedical Chromatography</i> , <b>2012</b> , 26, 1519-28	1.7	65
87	Renal tubular secretion of varenicline by multidrug and toxin extrusion (MATE) transporters. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 563-9	2.2	15
86	Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, 526-30	3	35
85	Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. <i>Human Mutation</i> , <b>2011</b> , 32, E1976-84	4.7	85
84	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 886-91	4	17
83	Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. <i>Journal of Biochemistry</i> , <b>2010</b> , 148, 557-63	3.1	2
82	Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. <i>Journal of Nutrition</i> , <b>2010</b> , 140, 1220-6	4.1	105
81	Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 298, F923-34	4.3	11
80	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 135-8	1.9	44
79	mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 67-76	6	20
78	Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 2022-33	4.5	52
77	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 821-6	4	32

76	Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2009</b> , 329, 185-91	4.7	155
75	SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2009</b> , 20, 2546-55	12.7	97
74	Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2009</b> , 24, 458-63	2.2	9
73	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. <i>Biochemical Pharmacology</i> , <b>2009</b> , 77, 1429-36	6	39
72	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. <i>Biochemical Pharmacology</i> , <b>2009</b> , 78, 1263-71	6	70
71	Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. <i>Biopharmaceutics and Drug Disposition</i> , <b>2009</b> , 30, 517-23	1.7	3
70	MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. <i>Pharmaceutical Research</i> , <b>2009</b> , 26, 1590-5	4.5	18
69	Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. <i>Digestive Diseases and Sciences</i> , <b>2009</b> , 54, 1347-54	4	43
68	A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. <i>Biological and Pharmaceutical Bulletin</i> , <b>2009</b> , 32, 99-104	2.3	16
67	Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2009</b> , 24, 175-9	2.2	3
66	Pharmacokinetic Interactions between Calcineurin Inhibitors and Azole Antifungals in Hematopoietic Stem Cell Transplant Recipients. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2009</b> , 35, 233-239	0.1	2
65	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. <i>Biochemical Pharmacology</i> , <b>2008</b> , 76, 894-903	6	72
64	Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 325, 610-6	4.7	16
63	Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 2299-306	4	81
62	Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2008</b> , 23, 313-7	2.2	13
61	Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2008</b> , 23, 469-75	2.2	9
60	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. <i>American Journal of Physiology - Cell Physiology</i> , <b>2008</b> , 295, C632-41	5.4	107
59	Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2008</b> , 23, 134-8	2.2	22



58	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 413-23	1.9	84
57	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. <i>Biochemical Pharmacology</i> , <b>2007</b> , 73, 1482-90	6	38
56	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. <i>Biochemical Pharmacology</i> , <b>2007</b> , 74, 477-87	6	186
55	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. <i>Biochemical Pharmacology</i> , <b>2007</b> , 74, 359-71	6	325
54	Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. <i>International Journal of Clinical Oncology</i> , <b>2007</b> , 12, 284-90	4.2	20
53	Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal failure. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2007</b> , 22, 419-27	2.2	14
52	INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. <i>Blood</i> , <b>2007</b> , 109, 306-14	2.2	92
51	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients <b>2006</b> , 112, 184-98		151
50	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing. <i>Liver Transplantation</i> , <b>2006</b> , 12, 292-300	4.5	16
49	Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2006</b> , 21, 122-5	2.2	28
48	Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2006</b> , 21, 492-500	2.2	5
47	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 319, 879-86	4.7	256
46	Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 2127-35	12.7	309
45	Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. <i>Biological and Pharmaceutical Bulletin</i> , <b>2006</b> , 29, 1441-4	2.3	4
44	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 119-27	1.9	101
43	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 90-102	6.1	39
42	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 331-45	6.1	79
41	Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. <i>Pharmaceutical Research</i> , <b>2006</b> , 23, 1696-701	4.5	110

40	Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. <i>Transplantation Proceedings</i> , <b>2005</b> , 37, 1728-9	1.1	22
39	Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2005</b> , 20, 200-5	2.2	30
38	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 168-81	6.1	66
37	Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. <i>Biochemical Pharmacology</i> , <b>2005</b> , 69, 561-8	6	24
36	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. <i>Biochemical Pharmacology</i> , <b>2005</b> , 70, 1823-31	6	129
35	Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. <i>Pharmaceutical Research</i> , <b>2005</b> , 22, 2016-22	4.5	34
34	Increased protein level of PEPT1 intestinal H <sup>+</sup> -peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>2005</b> , 288, G664-70	5.1	6
33	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2005</b> , 20, 379-86	2.2	275
32	Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 312, 816-25	4.7	32
31	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 3569-74	11.5	243
30	Gene expression variance based on random sequencing in rat remnant kidney. <i>Kidney International</i> , <b>2004</b> , 66, 29-45	9.9	15
29	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. <i>Pharmaceutical Research</i> , <b>2004</b> , 21, 61-7	4.5	80
28	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. <i>Journal of Human Genetics</i> , <b>2004</b> , 49, 40-45	4.3	27
27	Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 75, 352-61	6.1	29
26	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 471-8		162
25	Decreased expression of glucose and peptide transporters in rat remnant kidney. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2004</b> , 19, 41-7	2.2	25
24	Cloning and characterization of a novel Na <sup>+</sup> -dependent glucose transporter (NaGLT1) in rat kidney. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 14669-76	5.4	37
23	Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2003</b> , 18, 91-103	2.2	21

22	Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. <i>Liver Transplantation</i> , <b>2003</b> , 9, 1108-13	4.5	23
21	Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2. <i>Biochemical Pharmacology</i> , <b>2003</b> , 66, 163-70	6	35
20	Na(+)-dependent fructose transport via rNaGLT1 in rat kidney. <i>FEBS Letters</i> , <b>2003</b> , 546, 276-80	3.8	19
19	Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. <i>Kidney International</i> , <b>2002</b> , 62, 514-24	9.9	116
18	Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. <i>Pharmaceutical Research</i> , <b>2002</b> , 19, 738-43	4.5	44
17	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 451-7		175
16	Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. <i>Journal of Surgical Research</i> , <b>2002</b> , 103, 215-22	2.5	39
15	Gene expression levels and immunolocalization of organic ion transporters in the human kidney. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 866-874	12.7	405
14	Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. <i>Kidney International</i> , <b>2001</b> , 60, 1058-68	9.9	37
13	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. <i>Pharmaceutical Research</i> , <b>2001</b> , 18, 1528-34	4.5	53
12	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 308-16	6.1	90
11	Expression of peptide transporter following intestinal transplantation in the rat. <i>Journal of Surgical Research</i> , <b>2001</b> , 99, 294-300	2.5	14
10	Interaction of Azole Antifungal Agents with Human P-glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1.. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2001</b> , 16, 5-11		
9	Upregulation of H(+)-peptide cotransporter PEPT2 in rat remnant kidney. <i>American Journal of Physiology - Renal Physiology</i> , <b>2001</b> , 281, F1109-16	4.3	35
8	Cellular and molecular aspects of drug transport in the kidney. <i>Kidney International</i> , <b>2000</b> , 58, 944-58	9.9	353
7	Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 98-103	6.1	88
6	Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. <i>Histochemistry and Cell Biology</i> , <b>2000</b> , 114, 175-80	2.4	67
5	Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. <i>Nephrology Dialysis Transplantation</i> , <b>2000</b> , 15 Suppl 6, 11-3	4.3	62

4	Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. <i>Pharmaceutical Research</i> , <b>1999</b> , 16, 534-9	4.5	33
3	Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. <i>FEBS Letters</i> , <b>1999</b> , 459, 128-32	3.8	31
2	mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. <i>FEBS Letters</i> , <b>1997</b> , 407, 127-31	3.8	73
1	Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 20719-25	5.4	150